drugset / Trial / NCT01292304

Tolvaptan for Ascites in Cirrhotic Patients

NCT01292304

NaSingle-groupOpen-labelTreatment

Summary

Open Label Study evaluating the safety and efficacy of tolvaptan in the treatment of ascites in liver cirrhosis. Tolvaptan will be administered in combination with current ascites management.

Timeline

Start
2012-03
Primary completion
2014-12
Completion
2015-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Tolvaptan Small molecule 30 mg Oral

Indications